Match!

Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency

Published on May 1, 2012in European Journal of Endocrinology5.107
· DOI :10.1530/EJE-11-1072
M. Elbornsson3
Estimated H-index: 3
(Sahlgrenska University Hospital),
G. Götherström6
Estimated H-index: 6
(Sahlgrenska University Hospital)
+ 3 AuthorsJohan Svensson33
Estimated H-index: 33
Abstract
There are few studies that have determined the effects of long-term GH replacement on bone mineral density (BMD) in GH-deficient (GHD) adults. In this study, the effects of 10 years of GH replacement on BMD were assessed in 87 GHD adults using dual energy X-ray absorptiometry (DEXA). The results show that GH replacement induced a sustained increase in BMD at all the skeletal sites measured. Introduction: Little is known of the effect of more than 5 years of GH replacement therapy on bone metabolism in GHD adults. Patients and methods: In this prospective, open-label, single-center study, which included 87 consecutive adults (52 men and 35 women; mean age of 44.1 (range 22-74) years) with adulthood onset GHD, the effect of 10 years of GH replacement on BMD was determined. Results: The mean initial dose of GH was 0.98 mg/day. The dose was gradually lowered and after 10 years the mean dose was 0.47 mg/day. The mean insulin-like growth factor-I (IGF-I) SDS increased from 1.81 at baseline to 1.29 at study end. The GH replacement induced a sustained increase in total, lumbar (L2-L4) and femur neck BMD, and bone mineral content (BMC) as measured by DEXA. The treatment response in IGF-I SDS was more marked in men, whereas women had a more marked increase in the total body BMC and the total body z-score. There was a tendency for women on estrogen treatment to have a larger increase in bone mass and density compared with women without estrogen replacement. Conclusions: Ten years of GH replacement in hypopituitary adults induced a sustained, and in some variables even a progressive, increase in bone mass and bone density. The study results also suggest that adequate estrogen replacement is needed in order to have an optimal response in BMD in GHD women.
  • References (62)
  • Citations (102)
📖 Papers frequently viewed together
249 Citations
650 Citations
223 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References62
Newest
#1A. P. Jorgensen (University of Oslo)H-Index: 1
#2Kristian J. FougnerH-Index: 16
Last. Jens Bollerslev (University of Oslo)H-Index: 48
view all 7 authors...
Abstract Objective The goal of growth hormone (GH) replacement is to improve quality of life (QoL) and prevent the long-term complications of GH deficiency (GHD). Thirty-nine patients with adult-onset GH deficiency (AOGHD) who had originally participated in a randomized placebo-controlled crossover study involving treatment with either GH or placebo for nine months were enrolled in an open, 33-month follow-up study of the effects on QoL as well as bone and metabolic parameters. Methods GH replac...
46 CitationsSource
#1WanWan Xu (University of Pittsburgh)H-Index: 1
#2Subashan Perera (University of Pittsburgh)H-Index: 45
Last. Susan L. Greenspan (University of Pittsburgh)H-Index: 69
view all 7 authors...
Abstract Background The presence of a vertebral fracture identifies a patient who has clinical osteoporosis. However, approximately 2/3 to 3/4 of VFs are asymptomatic. Vertebral Fracture Assessment is a method derived from dual-energy X-ray absorptiometry (DXA) to assess vertebral fractures. The objectives of this study were 1) to determine the association between the degree of height loss in older men and women and the risk of a vertebral fracture, and 2) to determine if the knowledge of verteb...
37 CitationsSource
Growth hormone (GH) replacement in adulthood results in variable bone responses as a function of the gonadic hormonal milieu. We performed a retrospective analysis of a large cohort of adult males and females with confirmed GH deficiency (GHD) prior to treatment and during 3 years of replacement therapy. Potential confounders and effect modifiers were taken into account. Sixty-four adult patients with GHD (20 females and 44 males; mean age 34 years, range 18–64) were included in the analysis. GH...
9 CitationsSource
#1L. Joseph Melton (Mayo Clinic)H-Index: 166
#2Elizabeth J. Atkinson (Mayo Clinic)H-Index: 80
Last. B. Lawrence Riggs (Mayo Clinic)H-Index: 105
view all 5 authors...
Bone mineral density (BMD) was measured at the lumbar spine and cervical and intertrochanteric regions of the proximal femur by dual-photon absorptiometry and bone mineral content was assessed at the distal and midradius by single-photon absorptiometry in an age-stratified random sample of 304 Rochester, Minnesota women aged 30–94 years. Over follow-up extending to 10 years (median 8.3 years), 93 women experienced 163 new fractures. After adjusting for age, these bone mineral measurements predic...
770 CitationsSource
Purpose of review Description of recent progress in our understanding of growth hormone (GH) effects on bone. Recent findings Growth hormone deficiency is associated with low bone mass in children and adults, in addition to its well established impact on growth. Although GH and insulin-like growth factor I have direct skeletal actions, it is also possible that disordered parathyroid hormone secretion or effect may mediate some of the deleterious consequences of GH deficiency on bone. The benefit...
29 CitationsSource
Objective: Adult patients with GH deficiency (GHD) are characterized by a reduced muscle mass, but also reduced bone mineral density (BMD) and content (BMC), which have been ascribed to GHD per se. The aim of this study was to investigate if changes in BMD/BMC in adult GHD patients could be due to a muscle modulating effect, and if treatment with GH would primarily increase muscle mass and strength with a secondary increase in BMD/BMC, thus supporting the present physiological concept that mass ...
14 CitationsSource
#1Gustavo Duque (UM: University of Miami)H-Index: 37
#2Bruce R. Troen (UM: University of Miami)H-Index: 26
Knowledge of the underlying mechanisms of osteoporosis in older adults has significantly advanced in recent years. There is an acute loss of bone mineral density in the peri-menopausal period, followed by a more gradual and progressive decline, which is also seen in men. Markedly increased bone resorption leads to the initial fall in bone mineral density. With increasing age, there is also a significant reduction in bone formation. This is mostly due to a shift from osteoblastogenesis to predomi...
94 CitationsSource
#1Helene Holmer (Lund University)H-Index: 9
#2Johan Svensson (Sahlgrenska University Hospital)H-Index: 33
Last. Eva Marie Erfurth (Lund University)H-Index: 33
view all 16 authors...
Fracture risk in GHD patients is not definitely established. Studying fracture incidence in 832 patients on GH therapy and 2581 matched population controls, we recorded a doubled fracture risk in CO GHD women, but a significantly lower fracture risk in AO GHD men. Introduction: The objective of this study was to evaluate fracture incidence in patients with confirmed growth hormone deficiency (GHD) on replacement therapy (including growth hormone [GH]) compared with population controls, while als...
50 CitationsSource
Background: To investigate women, with height loss of more than three cm, without earlier diagnosed spinal fractures, for osteoporosis and vertebral fractures.Methods: Consecutively enrolment of women aged 50–85 years with a height loss of three cm or more. 80 women with a mean age of 70 years old (51–84) were recruited. Determination was made of bone mineral density (BMD) with DXA technique on hip, lumbar spine and whole body. Lateral spine radiographs were performed on thoracic and lumbar spin...
7 CitationsSource
#1Mark E. Molitch (NU: Northwestern University)H-Index: 73
#2David R. Clemmons (UNC: University of North Carolina at Chapel Hill)H-Index: 95
Last. Mary Lee Vance (UVA: University of Virginia)H-Index: 56
view all 5 authors...
Growth hormone treatment can provide benefits in body composition, bone, and quality of life in adults with confirmed growth hormone deficiency.
650 CitationsSource
Cited By102
Newest
#1Ilonka Kreitschmann-Andermahr (University of Duisburg-Essen)H-Index: 20
#2S Siegel (University of Duisburg-Essen)H-Index: 7
Last. Kathrin ZopfH-Index: 4
view all 14 authors...
INTRODUCTION: While reasons for non-adherence in children requiring growth hormone (GH) replacement (GH-Rx) are well researched, few studies have investigated adherence in adult GH deficient patients. Against the background of the adverse medical sequelae of untreated severe GH deficiency (GHD) in adults, we explored adherence to GH-Rx and associated factors in this patient group. METHOD: Cross-sectional analysis including 107 adult patients with severe GHD on GH-Rx, 15 untreated GDH patients an...
Source
#1Mirjana DoknicH-Index: 17
#2Vladimir GasicH-Index: 2
Last. Ivan SoldatovicH-Index: 17
view all 11 authors...
: Twenty years after the first description of combined hypopituitarism (CPHD) caused by PROP1 mutations, the phenotype of affected subjects is still challenging for clinicians. These patients suffer from pituitary hormone deficits ranging from IGHD to panhypopituitarism. ACTH deficiency usually develops later in life. Pituitary size is variable. PROP1 mutation is the most frequent in familial congenital hypopituitarism (CH). Reports on initiation of hormonal replacement including growth hormone ...
Source
#1Xin He (UM: University of Michigan)
#2Ariel L. Barkan (UM: University of Michigan)H-Index: 45
Growth hormone (GH) therapy has been studied as treatment for clinical manifestations of adult-onset growth hormone deficiency (AO-GHD), including cardiovascular risk, bone health, and quality of life. Patients with AO-GHD typically also have significant history of pituitary pathology and hypopituitarism, which raises the question of what proportion of their clinical presentation can be attributed to GHD alone. Currently, much of the existing data for GH therapy in AO-GHD come from uncontrolled ...
Source
#1Charlotte Höybye (Karolinska University Hospital)H-Index: 24
#2Pia Burman (Lund University)H-Index: 28
Last. Anders F Mattsson (Pfizer)H-Index: 18
view all 7 authors...
Objective: Clinical observations over time of adults with growth hormone (GH) deficiency (GHD) have indicated a shift in patient characteristics at diagnosis. The objective of this study was to compare baseline characteristics of patients diagnosed with adult-onset GHD naive to GH replacement during t hree study periods (1994-1999 (P1), 2000-2004 (P2), and 2005-2012 (P3)) using the KIMS (Pfizer's International Metab olic) database. Methods: Data were retrieved for a total of 6069 patients with a...
Source
#1Martin Kužma (Comenius University in Bratislava)H-Index: 5
#2Zdenko KillingerH-Index: 11
Last. Juraj PayerH-Index: 17
view all 7 authors...
: This article is focused on endocrine-mediated osteoporosis caused by growth hormone (GH) disorders; adult GH deficiency and acromegaly. GH and insulin like growth factor-1 (IGF-1) stimulate linear bone growth through complex hormonal interactions and activates epiphyseal prechondrocytes. GH, via receptor activator of nuclear factor-kappaB (RANK), its ligand (RANK-L), and the osteoprotegerin system, stimulates production of osteoprotegerin and its accumulation in bone matrix. Malfunction of thi...
Source
#1Kevin C. J. Yuen (UA: University of Arizona)H-Index: 22
#2Sofia Llahana (City University London)H-Index: 6
Last. Bradley S. Miller (UMN: University of Minnesota)H-Index: 19
view all 3 authors...
AbstractIntroduction: There have been significant clinical advances in the understanding of the diagnosis and benefits of long-term recombinant human growth hormone (rhGH) replacement in adults wit...
2 CitationsSource
#1Hongbo YangH-Index: 10
Last. Hui PanH-Index: 14
view all 9 authors...
: Context Adult growth hormone deficiency (AGHD) is characterized by low bone density and increased risk of fracture. Bone microarchitecture is insufficiently evaluated in patients with childhood-onset AGHD (CO AGHD). Objective To assess volumetric bone density (vBMD) and bone microarchitecture in CO AGHD in early adulthood after cessation of recombinant growth hormone (rhGH) treatment. Design and subjects Case-control study in a major academic medical center in Beijing, including 20 young male ...
Source
Sheehan’s syndrome (SS) is an important cause of pan-hypopituitarism in women. There is scanty information on bone mineral density (BMD) in this condition. We determined BMD and the changes in BMD after oestrogen (E2) replacement and nutritional supplementation in women with SS. In a cross-sectional study, BMD was measured by DEXA in 83 patients [age (mean ± SD) 42 ± 9.2 years] and compared with an equal number of matched controls. In a sub-set of 19 patients, we conducted an open-label, prospec...
1 CitationsSource
#1Wassim Chemaitilly (St. Jude Children's Research Hospital)H-Index: 12
Hypothalamic pituitary (HP) dysfunction is frequently observed in survivors of childhood cancer and brain tumors. The main risk factors are tumor growth and/or surgery or radiotherapy involving the HP region. Radiation-induced HP dysfunction most frequently occurs as a late effect, months to years after the completion of cancer/tumor therapy. Systematic assessments where CCS are periodically screened based on their cancer/tumor treatment history allow the early diagnosis and treatment of this co...
Source
#1Elena V. Varlamov (OHSU: Oregon Health & Science University)H-Index: 3
#2Shirley McCartney (OHSU: Oregon Health & Science University)H-Index: 17
Last. Maria Fleseriu (OHSU: Oregon Health & Science University)H-Index: 27
view all 3 authors...
Abstract Patients with growth hormone (GH) deficiency have decreased bone mineral density (BMD) and higher risk of fractures. Younger age, severe GHD, longer period of interruption of GH treatment before achievement of peak bone mass, un-replaced sex steroids or over replacement of glucocorticoid or thyroid deficiencies may contribute to lower BMD in GHD patients. Positive BMD change has been noted in prospective trials after at least a year of GH replacement and may persist for up to 10–15 year...
2 CitationsSource